

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*
(A joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

**PROPOSED CHANGE OF THE COMPANY NAME
PROPOSED CHANGE OF REGISTERED ADDRESS OF THE COMPANY
AND
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The board (the “**Board**”) of directors (the “**Directors**”) of Northeast Tiger Pharmaceutical Co., Ltd.* (the “**Company**”) announces that resolutions will be proposed at the extraordinary general meeting to be held by the Company (the “**EGM**”) to consider and approve (i) the proposed change of the Chinese name of the Company from “東北虎藥業股份有限公司” to “北斗嘉藥業股份有限公司” and the English name of the Company from “Northeast Tiger Pharmaceutical Co., Ltd.” to “Baytacare Pharmaceutical Co., Ltd.”; (ii) the proposed change of registered address of the Company; and (iii) the proposed amendments to the articles of association of the Company.

PROPOSED CHANGE OF THE COMPANY NAME

The Board proposes to change the Chinese name of the Company from “東北虎藥業股份有限公司” to “北斗嘉藥業股份有限公司” and the English name of the Company from “Northeast Tiger Pharmaceutical Co., Ltd.” to “Baytacare Pharmaceutical Co., Ltd.” (the “**Proposed Change of the Company Name**”), subject to the conditions as set out in the paragraph headed “Conditions” below.

Conditions

The Proposed Change of the Company Name will be subject to the following:

- (1). the passing of an ordinary resolution by the shareholders (the “**Shareholders**”) of the Company at the EGM to approve the Proposed Change of the Company Name; and

- (2). any necessary approval of the relevant authorities in the People's Republic of China (the "PRC") in relation to the Proposed Change of the Company Name being obtained.

The relevant filing with the relevant authorities in the PRC will be made after the passing of the relevant ordinary resolution at the EGM. Subject to the satisfaction of the conditions set out above, the Proposed Change of the Company Name will take effect from the date of completion of the registration of change in company name with the relevant industry and commerce bureau in the PRC. The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

Reasons for the change of the Company name

The change of the Company name is made due to the fact that our Group is mainly engaged in (i) pharmaceutical business; and (ii) the development of civilian use of Beidou and big data. The Board considers that the change of the Company name can better reflect the Group's nature and major activities. The proposed new company name will provide the Company with a more distinctive corporate profile or identity. Accordingly, the Board believes that the change of the Company name is in the best interests of the Company and the Shareholders as a whole.

Effects of the Proposed Change of the Company Name

The Proposed Change of the Company Name will not affect any rights of the holders of securities of the Company or the Company's daily business operation and/or financial position. All existing certificates of securities in issue bearing the present name of the Company shall, after the Proposed Change of the Company Name becoming effective, continue to be evidence of title to such securities and the existing share certificates will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for exchange of the existing certificates of securities for new certificates bearing the new name of the Company. Once the Proposed Change of the Company Name becomes effective, new share certificates will be issued only in the new name of the Company.

In addition, subject to the confirmation of The Stock Exchange of Hong Kong Limited, the English stock short name and the Chinese stock short name for trading in the shares of the Company will also be changed after the Proposed Change of the Company Name becomes effective.

PROPOSED CHANGE OF REGISTERED ADDRESS OF THE COMPANY

As invited by Qianhai Shenzhen – Hong Kong Cooperation Zone, the Board proposes to change the registered address of the Company from “No.3, No. 2 Road, Jilin Hi-Tech Development Zone, Jilin City, Jilin Province, the People’s Republic of China” to “Room 201, Block A, No. 1 Qian Wan Yi Road, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen, the People’s Republic of China (premises of Shenzhen Qianhai Business Secretarial Company Limited) ” (the “**Proposed Change of Registered Address of the Company**”), subject to the conditions as set out in the paragraph headed “Conditions” below.

Conditions

The Proposed Change of Registered Address of the Company will be subject to the following:

- (1). the passing of an ordinary resolution by the Shareholders at the EGM to approve the Proposed Change of Registered Address of the Company; and
- (2). any necessary approval of the relevant PRC authorities in relation to the Proposed Change of Registered Address of the Company being obtained.

The relevant filing with relevant PRC authorities will be made after the passing of the relevant ordinary resolution at the EGM. Subject to the satisfaction of the conditions set out above, the Proposed Change of Registered Address of the Company will take effect from the date of completion of the registration of change in its registered address with the relevant industry and commerce bureau in the PRC.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Taking into account the Proposed Change of the Company Name, the Proposed Change of Registered Address of the Company, the change in registered capital of the Company as a result of the allotment of new domestic shares of the Company on 11 November 2016 and the allotment of new H shares of the Company on 20 September 2016 and the actual conditions of the Company, the Board proposes to make amendments to the articles of association of the Company.

Particulars of the proposed amendments to the articles of association of the Company (the “**Proposed Amendments to the Articles of Association**”) are set out below:

Article 1:

Existing Article

“Northeast Tiger Pharmaceutical Co., Ltd (the “**Company**”) is a company limited by shares established in accordance with the Company Law of the People’s Republic of China (the “**Company Law**”).

Following approval by Document 200118 of Jilin Provincial Government and Document Jigaigu Number 200017 of the Jilin Provincial Commission for Economic Restructuring, the Company was established by means of promotion, and registered with the Jilin Provincial Administration for Industry and Commerce and obtained a body corporate business license on June 30, 2000. The original registration number of the business license was 2200001004702.

The promoters of the Company are Jilin Yuandong Pharmaceutical Group Company Limited, Xu Zhe, Xu Daotian, Li Shulian, Liu Xiaohong, Zhang Yabin and Leng Zhanren.”

Amended Article

“Baytacare Pharmaceutical Co., Ltd (the “**Company**”) is a company limited by shares established in accordance with the Company Law of the People’s Republic of China (the “**Company Law**”).

Following approval by Document 200118 of Jilin Provincial Government and Document Jigaigu Number 200017 of the Jilin Provincial Commission for Economic Restructuring, the Company was established by means of promotion, and registered with the Jilin Provincial Administration for Industry and Commerce and obtained a body corporate business license on June 30, 2000. The original registration number of the business license was 2200001004702.

The promoters of the Company are Jilin Yuandong Pharmaceutical Group Company Limited, Xu Zhe, Xu Daotian, Li Shulian, Liu Xiaohong, Zhang Yabin and Leng Zhanren.”

Article 2:

Existing Article

Registered name of the Company:

Chinese: 東北虎藥業股份有限公司

English: Northeast Tiger Pharmaceutical Company Limited

Amended Article

Registered name of the Company:

Chinese: 北斗嘉藥業股份有限公司

English: Baytacare Pharmaceutical Co., Ltd.

Article 3:

Existing Article

Domicile of the Company: No.3, No.2 Road, Jilin High-tech Development Zone, Jilin Province, the PRC

Postal Code: 132013

Telephone: 0432-64641900

Facsimile: 0432-64879802

Amended Article

Domicile of the Company: Room 201, Block A, No. 1 Qian Wan Yi Road, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen, the People's Republic of China (premises of Shenzhen Qianhai Business Secretarial Company Limited)

Postal Code: 518054

Telephone: 0755-82123125

Facsimile: 0755-82121410

Article 23:

First stage of amendment:

Existing Article

The registered share capital of the Company is RMB74,665,424.

Amended Article

The registered share capital of the Company is RMB78,805,424.

Reasons for the amendments:

As disclosed in the announcement of the Company dated 20 September 2016, the Company had completed the issuance of 41,400,000 new H shares of the Company on 20 September 2016 (the "**H Shares Issuance**"). Immediately upon the completion of the H Shares Issuance, the registered capital of the Company was increased to RMB78,805,424.

For the avoidance of doubt, the above amendment is made solely for the purpose of registration with the relevant industry and commerce bureau in the PRC and will not be reflected in the revised Articles of Association.

Second stage of amendment:

Existing Article (after taking into account the above first stage of amendment)

The registered share capital of the Company is RMB78,805,424.

Amended Article

The registered share capital of the Company is RMB85,805,424.

Reasons for the amendments:

As disclosed in the announcement of the Company dated 11 November 2016, the Company had completed the issuance of 70,000,000 new domestic shares of the Company on 11 November 2016 (the “**Domestic Shares Issuance**”). Immediately upon the completion of the Domestic Shares Issuance and the H Shares Issuance, the registered capital of the Company was increased to RMB85,805,424.

The English version of the articles of association of the Company and the above proposed amendments are an unofficial translation of its Chinese version prepared for reference only. In case of discrepancy between the two versions, the Chinese version shall prevail.

The above amendments to the articles of association of the Company are subject to, and shall take effect only upon, the passing of the special resolutions at the EGM.

GENERAL

A circular containing, among other matters, details of the Proposed Change of the Company Name, the Proposed Change of Registered Address of the Company and the Proposed Amendments to the Articles of Association and the notice of the EGM will be despatched to the Shareholders as soon as practicable.

By Order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Jilin, the People’s Republic of China, 28 November 2016

As at the date of this announcement, the executive Directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the non-executive Directors are Guo Aiqun and Cao Yang and the independent non-executive Directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited at <http://www.hkgem.com> for at least 7 days from the day of its posting and the Company’s website at <http://www.northeasttiger.com> from the date of this announcement.

** For identification purpose only*